Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Enzyme Research
Study data from Amgen, Inc., Department of Medicinal Chemistry provide new insights into enzyme research
May 16th, 2008
Scientists discuss in 'Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation' new findings in enzyme research. According to recent research from the United States, "A series of naphthyl-based compounds were synthesized as potential inhibitors of vascular endothelial growth factor (VEGF) receptors. Investigations of structure-activity relationships led to the identification of a series of naphthamides that are potent inhibitors of the VEGF receptor tyrosine kinase family." "Numerous analogues demonstrated low nanomolar inhibition of VEGF-dependent human umbilical vein endothelial cell...
Source: Health Business Week (2008-05-16)
|
